Blood-Based Biomarkers
A Scalable Approach to Meet the Growing Patient Demand
Early and accurate diagnosis of Alzheimer’s helps patients make more informed decisions on their care journeys, including considering lifestyle and therapeutic interventions. Disease-modifying treatments that target the underlying neuropathology of Alzheimer’s are here. Blood tests, also known as blood-based biomarkers (BBMs) are critical to ensuring patients and their providers can receive accurate and timely information to complement their clinical assessments.
Major Benefits of BBMs
Current research shows BBMs hold promising potential to transform the Alzheimer’s diagnostic pathway and patient journey.
Scalable & Accessible
Blood tests can scale faster than other tools because they don't need highly specialized staff or equipment. These tests are easier and less expensive to administer, particularly in primary care settings where the vast majority of the initial diagnoses of symptomatic Alzheimer’s are made. This can ultimately alleviate the strain on specialty care where appointment wait times are already extremely long.
Safe & Equitable
Blood tests are less invasive and seen as safe and acceptable by most patients, including patients from traditionally underserved groups. Blood collection is less costly and is already well-established in clinical routine, making them more available to individuals in rural areas or far from specialty diagnostic centers.
BBMs are Rapidly Being Integrated into Clinical Practice
BBMs are already being used across a number of patient groups and provider types.
To facilitate broader implementation in secondary, primary care, and community health settings, it is critical that health systems and healthcare providers are prepared, educated, and informed about this diagnostic tool.
See How the Performance of Available Blood Tests Compares to CEOi’s Standards
Educational Resources For
Blood-Based Biomarkers
View Additional BBM Resources Here
About the Blood-Based Biomarker Workgroup
The Global CEO Initiative on Alzheimer’s Disease (CEOi) is leading a global effort to prepare for the widespread adoption of Alzheimer’s blood-based biomarker (BBM) tests into clinical practice to enable a more simple, timely, and accurate diagnostic experience for patients.